Adaptimmune Therapeutics plc (ADAP) Social Stream



Adaptimmune Therapeutics plc (ADAP): $2.89

-0.06 (-2.03%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add ADAP to Watchlist
Sign Up

Industry: Biotech


Ranked

of 459

in industry

Adaptimmune Therapeutics PLC (ADAP) Price Targets From Analysts

The tables below show the price targets and recommendations analysts covering ADAP.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Current Price Upside Potential
2022-01-14 5 $17 $7 $10.333 $2.95 250.27%

ADAP reports an average of 143.26% for its upside potential over the past 71 days.

Date Number of Analysts Highest Target Price Lowest Target Price Average Target Price Share Price Upside Potential
2021-11-11 5 17 7 10.333 4.70 119.85%
2022-01-14 5 17 7 10.333 3.30 213.12%
2021-11-04 5 17 7 10.333 5.25 96.82%

ADAP Broker Recommendations Summary

Average Broker Rating Strong Buy Buy Hold Sell Strong Sell Analysts Issuing Recs
2.6 2 0 2 1 1 5

The bullet points below may help you gain a better understanding of what the metrics in the price target and recommendations tables above mean for ADAP as an investment opportunity.

  • Adaptimmune Therapeutics PLC's variance in analysts' estimates is lower than 6.88% of all US stocks.
  • Adaptimmune Therapeutics PLC's average analyst price target is higher than 16.78% of Healthcare stocks.
  • To contextualize these metrics, consider that out of stocks in the small market cap category, Adaptimmune Therapeutics PLC's upside potential (average analyst target price relative to current price) is greater than 77.97% of them.
  • ADAP has a greater number of analysts covering the stock than 65.9% of stocks in the small market cap category.

Stocks similar to Adaptimmune Therapeutics PLC in the Pharmaceutical Products industry regarding analyst recommendations and price targets are ACOR, ACHL, and ABOS.

Is ADAP a Buy, Hold or Sell? See the POWR Ratings now!


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!




Page generated in 0.7361 seconds.